Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APA-01 is a novel small molecule phenethylamine derivative developed by PharmAla Biotech. It is designed as a potent entactogen with an improved safety pharmacology profile compared to MDMA. Mechanistically, APA-01 acts as a 5-HT1A receptor agonist, a feature that distinguishes it from traditional MDMA and potentially expands its therapeutic applications. The compound is intended to promote the regrowth of neuronal connections in damaged brain regions, suggesting potential utility in treating neurological disorders such as traumatic brain injury (TBI) and stroke. Additionally, it is being explored for neuropsychiatric conditions, including fear disorders and psychological trauma. As of late 2024, APA-01 is in preclinical development, with animal research data highlighting its MDMA-like effects without the associated safety concerns of the parent compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on APA-01.